$4,420,000 of PFIZER INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Intellectual Property Protections Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues International Supply Chain Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competiveness Issues Trade Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
PFE Congressional Stock Trading
Members of Congress have traded $PFE stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 2 purchases worth up to $30,000 on 02/10, 11/18 and 2 sales worth up to $30,000 on 03/13, 12/19.
- REPRESENTATIVE J. FRENCH HILL sold up to $250,000 on 12/31.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
PFE Hedge Fund Activity
We have seen 1,256 institutional investors add shares of PFE stock to their portfolio, and 1,418 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 101,068,901 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $2,516,615,634
- NORGES BANK removed 20,119,761 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $500,982,048
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 17,862,459 shares (-96.2%) from their portfolio in Q4 2025, for an estimated $444,775,229
- PACER ADVISORS, INC. removed 17,574,851 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $437,613,789
- MORGAN STANLEY added 14,342,946 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $357,139,355
- BANK OF NEW YORK MELLON CORP added 13,581,757 shares (+38.9%) to their portfolio in Q4 2025, for an estimated $338,185,749
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 8,837,922 shares (-70.2%) from their portfolio in Q4 2025, for an estimated $220,064,257
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PFE Analyst Ratings
Wall Street analysts have issued reports on $PFE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/24/2025
To track analyst ratings and price targets for PFE, check out Quiver Quantitative's $PFE forecast page.
PFE Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 11 analysts offer price targets for $PFE in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Jin Zhang from CICC set a target price of $33.0 on 04/16/2026
- Michael Yee from UBS set a target price of $27.0 on 04/13/2026
- Terence Flynn from Morgan Stanley set a target price of $28.0 on 04/10/2026
- Jason Gerberry from B of A Securities set a target price of $26.0 on 04/09/2026
- Vamil Divan from Guggenheim set a target price of $36.0 on 03/24/2026
- Rajesh Kumar from HSBC set a target price of $32.0 on 03/17/2026
- David Toung from Argus Research set a target price of $35.0 on 03/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
